X0306 4 2020-06-10 false 0001689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN 0001704251 Tilton John C/O BIOHAVEN PHARMACEUTICALS, INC. 215 CHURCH STREET NEW HAVEN CT 06510 false true false false Chief Commercial Officer Common Shares 2020-06-10 4 M false 52000.00 9.29 A 52770.00 D Common Shares 2020-06-10 4 S false 21364.00 66.7027 D 31406.00 D Common Shares 2020-06-10 4 S false 22838.00 67.5293 D 8568.00 D Common Shares 2020-06-10 4 S false 5331.00 68.5665 D 3237.00 D Common Shares 2020-06-10 4 S false 2467.00 69.3968 D 770.00 D Employee Stock Option (right to buy) 9.29 2020-06-10 4 M false 52000.00 0.00 D 2027-01-30 Common Shares 52000.00 37292.00 D These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.05 - $67.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.05 - $68.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.05 - $68.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.05 - $69.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The shares underlying this option vested as to 50% of the shares on January 31, 2017, with the remainder vesting in 2 equal installments on the first and second anniversaries of the grant date, subject to the reporting person's continued service as of each applicable vesting date. /s/ Jim Engelhart, Attorney-in-Fact 2020-06-12